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The 2nd International Congress on Immunopharmacology
was held in June of 2011 at the Conference Center of
Plaza America in Varadero, Cuba. The main goal of this
meeting was to provide state-of-the-art communications
for scientists, manufacturers, regulators and healthcare
workers, to accelerate progress in the development of
biological and biotechnological products and to promote
exchange/scientific cooperation between researchers. 300
delegates from 22 countries attended the conference. The
wide-ranging programme commenced with a plenary ses-
sion and then split into a series of parallel workshops and
symposia, covering “Advances in Immunopharmacology”,
“Neuroimmunology”, “Therapeutic Biological Products”,
“Prophylaxis and Treatment of Helicobacter pylori”,
“Pharmacology of Cytochrome P450”, “Hereditary Ataxias”
and “Delivery Systems and Current Strategies for Drug
Design”. In this last Symposium, a substantial body of data
was presented relating to the development of delivery sys-
tems with adjuvant and vaccine potential and also to stra-
tegies focused in therapeutic and prophylactic approaches
against tuberculosis. This issue is dedicated to some of the
results presented in this area.
Particulated structures have been used for more than
two decades in the formulation of vaccine candidates,
even before nanotechnology became a common field on
its own. Virus-like particles and outer membrane vesicles
(OMV) based vaccines were shown to have prophylactic
potential against various infections [1]. Soluble antigens
obtained through recombinant or synthetic processes
have been known to be less immunogenic than antigens
associated with nanoparticles [2]. Traditional inactivated
and attenuated whole vaccines have immunostimulatory
components, like LPS and DNA, which also account for
toxic reactions associated to such vaccines. However,
these molecules, which are also referred to as natural
adjuvants [3], may trigger signals to activate cellular path-
ways that potentiate the immune response to antigens in
the vaccine formulation [3]. Development of bacterial
derived nano/microparticles takes advantage of such
immunostimulatory effects of the antigenic repertoire
expressed in the outer membrane of microorganisms [4].
OMV vaccines against Neisseria meningitidis serogroup
B were developed as both adjuvant [4] and vaccine [1].
Furthermore, OMV and cochleates obtained from bac-
teria have been effectively used via the mucosal route to
induce systemic as well as mucosal immune responses
[5]. This and other approaches have promoted research
and development of novel particulated structures from
Vibrio cholerae, Bordetella pertussis, N. meningitidis and
Mycobacteria [6,7]. Presentations related with these areas
are included in this supplement. Research related with
the identification of antigens of M. tuberculosis with vac-
cine potential using in silico methods as well as work
related with potential markers of tuberculosis infection
are also included.
The potential importance of the specific antibody
response against tuberculosis is a subject of growing
interest [8-14] and a report on the protective role of
antibody formulations against mycobacteria is also
presented.
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